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Abstract
Background:  CCR5 and CXCR4 are the two main coreceptors essential for HIV entry.
Therefore, these chemokine receptors have become important targets in the search for anti-HIV
agents. Here, we describe the establishment of a novel CD4+ cell line, U87.CD4.CCR5.CXCR4,
stably expressing both CCR5 and CXCR4 at the cell surface.
Results: In these cells, intracellular calcium signalling through both receptors can be measured in
a single experiment upon the sequential addition of CXCR4- and CCR5-directed chemokines. The
U87.CD4.CCR5.CXCR4 cell line reliably supported HIV-1 infection of diverse laboratory-adapted
strains and primary isolates with varying coreceptor usage (R5, X4 and R5/X4) and allows to
investigate the antiviral efficacy of combined CCR5 and CXCR4 blockade. The antiviral effects
recorded in these cells with the CCR5 antagonist SCH-C and the CXCR4 antagonist AMD3100
were similar to those noted in the single CCR5- or CXCR4-transfected U87.CD4 cells.
Furthermore, the combination of both inhibitors blocked the infection of all evaluated HIV-1 strains
and isolates.
Conclusions: Thus, the U87.CD4.CCR5.CXCR4 cell line should be useful in the evaluation of
CCR5 and CXCR4 antagonists with therapeutic potential and combinations thereof.
Background
After binding to the cellular CD4 receptor, HIV needs to
bind one of the chemokine receptors CCR5 and CXCR4 to
actually infect its target cells. CCR5 is the main coreceptor
for R5 (M-tropic) viruses that are mainly isolated from
patients in the early (asymptomatic) stage of HIV-infec-
tion. The more pathogenic X4 viruses that use CXCR4 as
their major coreceptor often emerge in HIV-infected per-
sons in a later stage of disease progression towards AIDS
[1-4].
These chemokine receptors CCR5 and CXCR4 belong to
the class of seven transmembrane G-protein coupled
receptors and their natural ligands are key players in the
recruitment of immune cells to sites of inflammation
[5,6]. In addition, chemokine receptors, and especially
CXCR4, are also implicated in several diseases, such as
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rheumatoid arthritis [7,8]., allergic airway disease [9], and
cancer [10-12]. Important ligands for CCR5 are the β-
chemokines 'regulated on activation normal T cell
expressed and secreted' (RANTES), and the 'macrophage
inflammatory proteins' MIP-1α and MIP-1β. The chemok-
ine MIP-1α occurs in two highly related isoforms, desig-
nated LD78α and LD78β, and although they only differ in
three amino acids, the LD78β isoform is much more
potent as a CCR5 agonist than LD78α [13]. Moreover,
LD78β is the most effective chemokine in inhibiting
CCR5-dependent HIV replication in peripheral blood
mononuclear cells (PBMCs) [13] and in human macro-
phages [14]. Unlike CCR5, the CXCR4 receptor has only
one known ligand, the α-chemokine 'stromal cell derived
factor' (SDF)-1. Since the natural CCR5 and CXCR4 lig-
ands and peptides derived thereof are capable to block the
entry of R5 and X4 HIV-1 viruses respectively, small-mol-
ecule CCR5 and CXCR4 antagonists would be most attrac-
tive new anti-HIV drugs [15-17].
The search for chemokine receptor antagonists has already
led to the discovery of several compounds with potent
antiviral activity in vitro, such as the CCR5 antagonists,
TAK-779 [18] and SCH-C [19], and the CXCR4 antago-
nist, AMD3100 [20-22]. The low molecular weight com-
pound AMD3100 (1,1'-[1,4-phenylenebis-(methylene)]-
bis-1,4,8,11-tetraazacyclo-tetradecane), the lead com-
pound of the bicyclams, shows antiviral activity in the
nanomolar concentration range against a wide range of
X4 and even dual tropic R5/X4 HIV-1 strains in PBMCs,
through specific binding to CXCR4 [21-25]. As AMD3100
does not interact with any chemokine receptor other than
CXCR4 and as the compound does not trigger any
response by itself, it can be considered as a highly specific
CXCR4 antagonist [26-28]. It was demonstrated that two
aspartate residues at positions 171 and 262 of CXCR4 are
crucial for the high-affinity binding of AMD3100 to
CXCR4 [29-31]. The compound SCH 351125, also called
SCH-C, is an oxime-piperidine compound with potent
activity against R5 HIV-1 strains. As shown by multiple
receptor binding and signal transduction assays, SCH-C is
a specific CCR5 antagonist [19]. Both AMD3100 and
SCH-C have shown in vivo antiviral efficacy in separate
clinical studies by reducing the plasma viremia in HIV-1-
infected persons [32,33]. These studies validated the
chemokine coreceptors CCR5 and CXCR4 as clinical drug
targets in the treatment of R5 and X4 HIV-1 infections,
respectively. However, it is assumed that the combined
use of a CCR5 and a CXCR4 antagonist will be necessary
to achieve profound HIV inhibition and subsequently
viral load decrease in HIV-infected persons.
The availibity of stable and reliable in vitro models is a pre-
requisite for the successful setup of an accurate screening
program for chemokine receptor antagonists. Here, we
have developed a double-transfected astroglioma cell line
expressing both CCR5 and CXCR4 in addition to the cel-
lular CD4 receptor, and we demonstrated its usefulness as
a tool to evaluate CCR5 and CXCR4 antagonists.
Results
Establishment of the U87.CD4.CCR5.CXCR4 cell line
Because of its complete lack of endogenous CCR5 or
CXCR4 expression, we used the U87.CD4 cell line as a
starting point to create a cell line highly suitable for the
evaluation of the anti-HIV activity of potential CCR5 and
CXCR4 antagonists. The chemokine receptors CCR5 and
CXR4 were stably transfected into the U87.CD4 cells
using FuGENE 6 Tranfection Reagent as described in
Materials and Methods.
After the transfection and selection procedure, we evalu-
ated CD4, CCR5 and CXCR4 expression at the cell surface
with mAb staining. We compared these data with the
expression of the receptors on U87.CD4 cells transfected
with either CCR5 or CXCR4 alone, that we previously
used for the antiviral evaluation of CCR5 or CXCR4 antag-
onists. As shown in Figure 1, all three cell lines highly
expressed the primary HIV-1 receptor CD4. In addition,
U87.CD4.CCR5.CXCR4 cells expressed CCR5 and CXCR4
at their surface with mean fluorescence intensity (MFI)
values of 55 and 142, respectively. Moreover, more then
95% of the cells are CCR5+/CXCR4+ double positive. The
U87.CD4.CCR5 and U87.CD4.CXCR4 single-transfected
cells expressed CCR5 or CXCR4, respectively, but com-
pletely lacked the other HIV-1 coreceptor (Figure 1).
Chemokine-induced intracellular calcium mobilization 
assays
To examine if transfection yielded a fully functional sur-
face receptor, we performed intracellular calcium mobili-
zation assays on these double-transfected cells and
compared their responses with those of the single-trans-
fected cell lines. We also evaluated the inhibitory effect of
the CCR5 antagonist SCH-C and the CXCR4 antagonist
AMD3100 on respectively the LD78β- and SDF-1-induced
calcium signalling in the double versus the single
transfectants.
To monitor chemokine-induced calcium responses, cells
were loaded with the fluorescent calcium indicator Fluo-3
and fluorescence was measured after chemokine stimula-
tion, using the FLIPR. To investigate the effects of SCH-C
and/or AMD3100, the cells were preincubated for 10 min-
utes with these compounds at different concentrations
prior to chemokine stimulation.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/2
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Figure 2A shows the concentration-dependent inhibitory
effects of SCH-C and AMD3100 in U87.CD4.CCR5 and
U87.CD4.CXCR4 cells (upper panels) and the double-
transfected cells (lower panels). The U87.CD4.CCR5 cells
were stimulated with LD78β at 100 ng/ml and the
U87.CD4.CXCR4 cells with SDF-1 at 20 ng/ml. The dou-
ble-transfected cells were stimulated by either chemokine
at the same concentration. The 50 % inhibitory concentra-
tions (IC50) of SCH-C for inhibition of LD78β-induced
calcium flux were 8 ng/ml in the single and 5 ng/ml in the
double-transfected cells. For AMD3100, the IC50 values
for inhibition of SDF-1-induced calcium mobilization
were 50 ng/ml and 53 ng/ml, in the single- and double-
transfected cells respectively.
The FLIPR system also allows sequential addition of two
chemokines to the same cells. This provides the opportu-
nity to examine the CCR5 and CXCR4 antagonism of a
single compound or a compound mix in the same test
plate. Fluo-3 loaded cells were preincubated with a mix-
ture of SCH-C and AMD3100, both at a final concentra-
tion of 1000 ng/ml each. Then intracellular calcium
mobilization was monitored, after stimulation with
LD78β followed by SDF-1. As shown in Figure 2B, the
combination of SCH-C and AMD3100, both at 1000 ng/
ml, completely blocked the Ca2+  responses towards
LD78β and SDF-1.
Flow cytometric analysis of the membrane expression of CD4, CCR5 and CXCR4 in the U87.CD4.CCR5.CXCR4 double- transfected cell line (3 panels, left column) and in the single-transfected U87.CD4.CCR5 cell line (3 panels, central column) and  U87.CD4.CXCR4 cell line (3 panels, right column) Figure 1
Flow cytometric analysis of the membrane expression of CD4, CCR5 and CXCR4 in the U87.CD4.CCR5.CXCR4 double-
transfected cell line (3 panels, left column) and in the single-transfected U87.CD4.CCR5 cell line (3 panels, central column) and 
U87.CD4.CXCR4 cell line (3 panels, right column). The gray curves represent staining by the specific CD4 (clone SK3), 
CXCR4 (clone 12G5) and CCR5 (clone 2D7) monoclonal antibodies in, respectively, the upper, central and lower row. The 
mean fluorescence intensity (MFI) of the CD4, CXCR4 and/or CCR5 positive cells is indicated in the right hand corner of each 
histogram. Aspecific background fluorescence is indicated by the white peaks.
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A. Concentration-dependent inhibition of LD78β- and SDF-1-induced intracellular calcium mobilization by SCH-C and  AMD3100 in CCR5- and CXCR4-transfected U87.CD4 cells and in the double-transfected U87.CD4.CCR5.CXCR4 cells Figure 2
A. Concentration-dependent inhibition of LD78β- and SDF-1-induced intracellular calcium mobilization by SCH-C and 
AMD3100 in CCR5- and CXCR4-transfected U87.CD4 cells and in the double-transfected U87.CD4.CCR5.CXCR4 cells. The 
Fluo-3 loaded cells were preincubated for 10 minutes with SCH-C at 200, 40, 8 and 1.6 ng/ml or AMD3100 at 1000, 200, 40 
and 8 ng/ml. Then U87.CD4.CCR5 cells were stimulated with LD78β at 100 ng/ml (upper left graph) and the U87.CD4.CXCR4 
cells were stimulated with SDF-1 at 20 ng/ml (upper right graph). U87.CD4.CCR5.CXCR4 cells were stimulated with either 
LD78β at 100 ng/ml (lower left graph) or SDF-1 at 20 ng/ml (lower right graph). The transient increase in intracellular calcium 
concentration was recorded by monitoring the change in green fluorescence intensity of the cells (y-axis) as function of time 
(x-axis) using the Fluorometric Imaging Plate Reader (FLIPR). Each data point represents the average value of the fluorescence 
measured in quadruplicate. The data of one representative experiment of four are shown. B. LD78β- and SDF-1-induced intra-
cellular calcium mobilization and blocking by SCH-C and AMD3100. Fluo-3 loaded cells were preincubated with a 1:1 combina-
tion of SCH-C and AMD3100 at 1000 ng/ml for 10 minutes, after which LD78β (100 ng/ml) and SDF-1 (20 ng/ml) were added 
sequentially at timepoints 20 seconds and 222 seconds respectively (arrows). The transient increase in intracellular calcium 
concentration was recorded by monitoring the change in green fluorescence intensity of the cells (y-axis) as function of time 
(x-axis) using the FLIPR. Each data point represents the average value of the fluorescence measured in quadruplicate. The data 
of one representative experiment out of four are shown.
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HIV-1 replication in U87.CD4.CCR5.CXCR4 cells
To investigate whether the U87.CD4.CCR5.CXCR4 cells
supported HIV-1 replication, we infected them with the
laboratory R5 strain BaL and X4 strain NL4.3 and the
dual-tropic (R5/X4) laboratory strain HE. We compared
their susceptibility to these HIV-1 strains with the
infectability of three CCR5-transfected T-cell lines, i.e. the
SupT1.CCR5, MOLT-4.CCR5 and Jurkat.CCR5 cells. After
5 days of infection, a strong cytopathic effect was visible
microscopically for NL4.3 and HE but not for BaL in the
SupT1.CCR5, MOLT-4.CCR5 and Jurkat.CCR5 cells (data
not shown). The failure of these cell lines to support R5
HIV-1 infection was quite unexpected, since they express
high amounts of CCR5 on their cell surface and in addi-
tion, they afford chemokine-induced Ca2+  fluxes and
chemotaxis through this receptor. On the other hand, the
R5 strain BaL induced strong cytopathicity in
U87.CD4.CCR5.CXCR4 cells, as well as the X4 strain
NL4.3 and the R5/X4 strain HE.
We also compared the infectability of the
U87.CD4.CCR5.CXCR4 cells and the antiviral activity of
the chemokine receptor inhibitors SCH-C and AMD3100
with that of the single-transfected cell lines
U87.CD4.CCR5 and U87.CD4.CXCR4. Table 1 presents
the inhibitory effects of the CCR5 antagonist SCH-C, the
CXCR4 antagonist AMD3100, and the CC-chemokines
RANTES and LD78β and the CXC-chemokine SDF-1 on
HIV-1 replication in the single-transfected cell lines. The
50% inhibitory concentration of SCH-C against replica-
tion of BaL in U87.CD4.CCR5 was 58 ng/ml whereas the
IC50 value of the compound against HE was 0.4 ng/ml.
Moreover, neither RANTES nor LD78β showed activity
against BaL. Their IC50 values against HE were 200 ng/ml
(RANTES) and 18 ng/ml (LD78β) (Table 1). AMD3100
strongly inhibited the NL4.3 and HE infection in
U87.CD4.CXCR4 cells with IC50 values that were similar
for both strains (3.6 and 3.3 ng/ml respectively). How-
ever, SDF-1 at concentrations up to 1000 ng/ml had no
blocking effect on the NL4.3 and HE HIV-1 replication in
these cells (Table 1).
Table 2 displays the antiviral activity of SCH-C and
AMD3100, used singly or in combination, in the double-
transfected U87.CD4.CCR5.CXCR4 cell line. As expected
AMD3100 did not have any effect when the cells were
infected with the R5 strain BaL. In contrast, for SCH-C, we
obtained an IC50 value of 39 ng/ml. The IC50 for the com-
bination (ratio 1:1) of SCH-C and AMD3100 was 102 ng/
ml. More precisely, the combination of both compounds
each at a final concentration of 102 ng/ml blocked the
replication of BaL for 50%. On the other hand, AMD3100
suppressed replication of the X4 strain NL4.3 with an IC50
value of 4.9 ng/ml, whereas SCH-C had no antiviral effect
against NL4.3. The IC50 value of the compound combina-
tion (ratio 1:1) against NL4.3 was 5.4 ng/ml. The single
agents had no inhibitory effect on the replication of the
dual-tropic HIV-1 strain HE. However, when combined at
equal concentrations, AMD3100 and SCH-C blocked in a
concentration-dependent manner the HE infection with
an IC50 value of 13 ng/ml. In fact, the mixture of both
compounds each at a final concentration of 200 ng/ml
inhibited HIV-1 HE replication by 99%, at 40 ng/ml the
percentage of inhibition was 63% and at 8 ng/ml the com-
binated inhibitors blocked viral replication by 18%.
Replication of HIV-1 clinical isolates in 
U87.CD4.CCR5.CXCR4 cells
To determine the infectability of the
U87.CD4.CCR5.CXCR4 cells by HIV-1 more in detail, we
investigated whether the cells could be infected with eight
clinical isolates with distinct coreceptor usage i.e. CI #6,
#14, #15, #19 (R5 isolates), CI #17 (X4 isolate) and CI
#10, #16, #18 (R5/X4 isolates). The coreceptor phenotype
of each of these viral isolates was determined using the
single-transfected U87.CD4.CCR5 and U87.CD4.CXCR4
Table 1: Inhibitory effects of SCH-C and AMD3100 on HIV-1 replication in U87.CD4.CXCR4 and U87.CD4.CCR5 cells.
IC50
a (ng/ml)
U87.CD4.CCR5 cells U87.CD4.CXCR4 cells
Virus strain Co-receptor 
Use
SCH-C RANTES LD78β AMD3100 SDF-1
BaL R5 58 >1000 >1000 NA NA
NL4.3 X4 NA NA NA 3.6 >1000
HE R5/X4 0.4 200 18 3.3 >1000
a Effect of AMD3100 and SCH-C and the chemokines SDF-1, RANTES and LD78β on the replication of laboratory HIV-1 strains BaL, NL4.3 and HE. 
Virus yield was monitored by p24 HIV-1 Ag ELISA o cell-free supernatant at 4–5 days after infection. NA = Not applicableRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/2
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cells. The R5 isolates completely failed to infect the
U87.CD4.CXCR4 cells, whereas the X4 isolate was unable
to replicate in U87.CD4.CCR5 cells.
U87.CD4.CCR5.CXCR4 cells were inoculated with the
viral isolates in the presence or absence of SCH-C and/or
AMD3100 at 1000 ng/ml each. After 5 days of infection,
the virus-induced cytopathic effect was observed micro-
scopically and the virus production was quantified in the
supernatant using a viral p24 core Ag ELISA (Figure 3).
Viral infection as assessed by both giant cell formation
and p24 Ag production was detected with all clinical iso-
lates used in this study. The p24 viral Ag concentrations
ranged from approximately 3600 up to 50000 pg/ml,
although the virus inoculum was carefully washed away
after the first two days of infection. As could be expected,
the infection of all R5 isolates (CI #6, #14, #15 and #19)
was completely blocked by SCH-C at 1000 ng/ml. Only
for CI #15 marginal residual p24 Ag production was
detected in the presence of SCH-C, although no giant cell
formation could be seen microscopically. The p24 viral Ag
production by the X4 isolate CI #17 could be completely
inhibited by AMD3100. Remarkably, AMD3100 also
inhibited to some extent the viral replication of the pure
R5 clinical isolates and, vice versa, SCH-C showed partial
activity against the X4 isolate CI #17. The dual-tropic iso-
late CI #10 could only be partially blocked by SCH-C or
AMD3100 alone. In contrast, the infection of the two
other dual-tropic isolates, CI #16 and #18, was totally
inhibited by AMD3100 and partially by SCH-C. Most
importantly, for all isolates, no viral replication could be
measured when U87.CD4.CCR5.CXCR4 cells had been
preincubated with the combination of SCH-C and
AMD3100 at 1000 ng/ml each. For CI #19 some minor
p24 Ag production was detected, but again, no giant cell
formation was visible microscopically.
Microscopic observations after 5 days of infection were in
full agreement these p24 core Ag ELISA data. Figure 4 dis-
plays the microscopic images obtained with CI#10 (R5/
X4 isolate), CI#14 (R5 strain) and CI#17 (X4 strain). In
agreement with the p24 data, separate administration of
SCH-C or AMD3100 at 1000 ng/ml could reduce syncy-
tium or giant cell formation by respectively the R5 isolate
CI #14 and the X4 isolate CI #17, but not cytopathicity of
the R5/X4 isolate CI #10. However, the combination of
both compounds completely inhibited giant cell forma-
tion by this dual-tropic HIV-1 isolate.
Discussion
This study was aimed at the development of a double-
transfected CCR5 and CXCR4 expressing cell line starting
from human atroglioma U87.CD4 cells. We have evalu-
ated this new cell line for its sensitivity towards HIV-1 and
chemokine-induced intracellular calcium mobilization
and demonstrated its usefulness for the evaluation of new
potential CCR5 and CXCR4 antagonists with potent anti-
viral activity.
We have selected the U87.CD4 cell line as the parental cell
line because of its many advantages over other cell lines.
U87.CD4 cells do not endogenously express CCR5 or
CXCR4 on their surface. On the contrary, other indicator
cell lines such as Hela, MAGI, GHOST and HOS cells
endogenously express CXCR4 on their cell surface, and
this could lead to false results [18,34-36]. Also, chemok-
ine receptor-transfected U87.CD4 cells proved to be
highly convenient for the evaluation of the effect of chem-
okine receptor inhibitors on chemokine-induced intracel-
lular calcium mobilization assays [30]. The fluorescent
calcium indicator Fluo3/AM, used to monitor the tran-
sient increase in intracellular Ca2+ concentration, is well
retained in these cells. Also, dye loading and washing pro-
cedures of these cells can easily be performed in the black-
wall 96-well tissue culture plates, in contrast to non-
adherent cells such as T-cell lines or PBMCs. Furthermore,
U87.CD4 cells expressing CCR5 or CXCR4 have been
commonly used for HIV replication assays and evaluation
of antiviral compounds [28,30,35,37]. Importantly,
U87.CD4.CCR5 cells support infection of all evaluated R5
and R5/X4 HIV-1 (and HIV-2) strains and clinical isolates.
In contrast, SupT1.CCR5, MOLT-4.CCR5 and Jur-
kat.CCR5 cells are easily infectable by X4 strains but,
unexpectedly, not by R5 strains. CCR5- or CXCR4-trans-
fected U87.CD4 cells are also widely used, and are even
Table 2: Inhibitory effects of SCH-C and AMD3100 on HIV-1 replication in U87.CD4.CXCR4.CCR5 cells.
IC50a (ng/ml)
Virus Strain Co-receptor use SCH-C AMD3100 SCH-C + AMD3100
BaL R5 39 >1000 102
NL4.3 X4 >1000 4.9 5.4
HE R5/X4 >1000 >1000 13
a Effect of AMD3100 and SCH-C on replication of laboratory HIV-1 strains BaL, NL4.3 and HE. Virus yield was monitored in the cell-free 
supernatant at 4–5 days after infection by p24 HIV-1 Ag ELISA.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/2
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Inhibitory effects of SCH-C and AMD3100 on replication of 8 different HIV-1 clinical isolates in U87.CD4.CCR5.CXCR4 cells Figure 3
Inhibitory effects of SCH-C and AMD3100 on replication of 8 different HIV-1 clinical isolates in U87.CD4.CCR5.CXCR4 cells. 
Viruses were added after 10 minutes of preincubation with SCH-C and AMD3100 at 1000 ng/ml or as a mixture of both at a 
1:1 ratio each at 1000 ng/ml. Viral p24 core Ag production (pg/ml) was measured by ELISA 5 days after infection of cells. The 
coreceptor use of each isolate is shown between brackets. The data of one representative experiment out of two are 
presented.
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Microscopic view of cytopathic effect (giant cell formation) at day 5 after infection of U87.CD4.CCR5.CXCR4 cells with the  clinical isolates CI #10, CI #14 and CI #17, which each have a different coreceptor use as shown between brackets Figure 4
Microscopic view of cytopathic effect (giant cell formation) at day 5 after infection of U87.CD4.CCR5.CXCR4 cells with the 
clinical isolates CI #10, CI #14 and CI #17, which each have a different coreceptor use as shown between brackets. Uninfected 
cells are shown as the negative control (upper row). Note the enormous giant cell formation in the untreated virus-infected 
cell cultures whereas such cytopathic effect is totally absent in infected cells exposed to a 1:1 combination of SCH-C and 
AMD3100 at 1000 ng/ml. Independently, SCH-C and AMD3100 prevented giant cell formation in cell cultures inoculated with 
R5 HIV-1 and X4 HIV-1, respectively, but not in cell cultures infected with the dual tropic R5/X4 HIV-1 isolate.
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preferred over the MT-2 assay, to determine the coreceptor
usage of HIV [4,35,38]. Although the MT-2 assay was use-
ful in determining SI/NSI (syncytium versus non-syncy-
tium inducing) phenotype of HIV variants [39], it has
been documented that NSI viruses as defined in the MT-2
assay turned out to be SI when evaluated in primary T-
cells, suggesting that viral isolates using CXCR4 could be
missed in the MT-2 cell line [40].
The U87.CD4.CCR5.CXCR4 cells express both receptors
on the cell surface as ascertained flow cytometrically and
were able to elicit an increase in intracellular calcium
concentration when stimulated with their corresponding
ligands. Also, the inhibitory effects of the CCR5 antago-
nist SCH-C and of the CXCR4 antagonist AMD3100 were
similar in the double- and single-transfected cell lines. The
U87.CD4.CCR5.CXCR4 cell line provides the opportunity
to simultaneously evaluate the CCR5 and CXCR4 antago-
nism of new compounds in one experiment by sequential
addition of the different chemokines.
The double-transfected cell line could be infected with the
laboratory strains BaL (R5), NL4.3 (X4) and HE (R5/X4).
The antiviral potency of SCH-C and AMD3100 against the
R5 strain BaL and the X4 strain NL4.3, respectively, was
similar in these cells compared with their anti-HIV activity
in the single-transfected cell lines. Moreover, their 50%
inhibition concentrations against respectively R5 and X4
viruses in the single- and double-transfected cell lines
were comparable with those obtained in PBMCs [19,22].
In addition, SCH-C or AMD3100 administered alone did
not block the infection of the R5/X4 laboratory strain HE
because this dual tropic strain can always escape via entry
through the other non-targeted receptor. Yet, the combi-
nation of both compounds concentration-dependently
blocked the replication of HE. Thus, the antiviral activity
of the antagonist combination should be interpreted dif-
ferently for the three laboratory HIV-1 strains. The activity
against BaL is most likely solely due to the interaction of
SCH-C with CCR5 and that against NL4.3 is established
by binding of AMD3100 to CXCR4. In case of the R5/X4
strain HE both inhibitors play an essential role and
showed additive activity.
In general, we noticed in the single-transfected cell lines
that the 50% inhibition concentrations of the CCR5
inhibitor SCH-C and the chemokines RANTES and LD78β
were always higher for inhibition of BaL than HE (≥ 8-
fold). Such HIV-1 strain-dependent variation in the anti-
viral activity of CCR5 inhibitors has previously also been
described by other groups [41]. All these variations are
presumably caused by the complex interaction between
the HIV-1 envelope and the chemokine receptor CCR5
and the variation in the V3 loop and other envelope
domains of the different HIV-1 strains [42,43].
We have demonstrated that the U87.CD4.CCR5.CXCR4
cells also support infection by 8 different HIV-1 clinical
isolates with distinct coreceptor usage. All R5 isolates were
completely blocked by the CCR5 antagonist SCH-C but
not by AMD3100, while the X4 isolate CI #17 was com-
pletely inhibited by AMD3100 but not by SCH-C. A puz-
zling observation was that the R5 isolates CI #14, #15 and
#19 were partially blocked by the CXCR4 antagonist
AMD3100 and the X4 isolate CI #17 seemed to be par-
tially inhibited by the CCR5 antagonist SCH-C. As both
compounds are highly specific, these phenomena could
not be assigned to aspecific binding of the CXCR4 antag-
onist AMD3100 to CCR5 or the CCR5 antagonist SCH-C
to CXCR4, [19,28]. Also, the pure X4 phenotype of CI #17
and the pure R5 phenotype of CI #14, #15 and #19 were
unequivocally verified by viral replication assays in
U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Therefore,
we hypothesize that this partial blocking of R5 viruses by
AMD3100 and of X4 virus by SCH-C is caused by distur-
bance of the membrane colocalization patterns of the
CD4 receptor and the appropriate coreceptor essential for
HIV-1 entry [44]. Indeed, the binding of a small-molecule
compound to a chemokine receptor may be assumed to
form a rigid complex [29]. This may impede the fluidity of
the membrane required for the actin-dependent receptor
colocalization induced by gp120-CD4 interaction [44].
Finally, none of the dual-tropic isolates were completely
blocked by SCH-C. On the other hand, two out of three
R5/X4 isolates were completely blocked by AMD3100.
These data are in line with previous data demonstrating
that AMD3100 on its own is able to block the infection of
R5/X4 isolates in PBMCs [45].
Most importantly, HIV infection was always completely
suppressed by the combination of the two receptor antag-
onists. These results are very promising because it has
been postulated that a combination these antagonists is
required to actually suppress HIV-1 infection. It has been
observed that when persons with a homozygous 32 bp
deletion, resulting in a lack of functional CCR5 receptors,
become infected with HIV-1, disease progression towards
AIDS is much faster [46], which is probably due to the
outgrowth of X4 viruses [47]. Also, in the separate Phase
II clinical studies with the two chemokine receptor antag-
onists, SCH-C and AMD3100, viruses that use the non-
targeted receptor could still be detected [32,33]. Other
groups have reported the combined use of different CCR5
and CXCR4 inhibitors as potent antiviral agents [48-50].
These studies illustrate the need for combination therapy
to treat infections with mixed virus isolates and multidrug
resistant viruses and suggest further clinical follow-up of
these observations.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/2
Page 10 of 13
(page number not for citation purposes)
Conclusions
This new CD4+/CCR5+/CXCR4+ cell line described here is
most valuable as a tool for high-throughput evaluation of
new CCR5 and CXCR4 inhibitors and in vitro evaluation
of their therapeutic potential in combination anti-HIV
therapy.
Materials and methods
Viruses
The M-tropic (R5) strain BaL was obtained from the MRC
(London, UK). The T-tropic (X4) HIV-1 molecular clone
NL4.3 was obtained from the National Institute of Allergy
and Infectious Disease AIDS Reagent program (Bethesda,
MD). The dual tropic (R5/X4) strain HE was initially iso-
lated from a patient at the University Hospital in Leuven,
and had been routinely cultured in MT-4 cells [51]. Virus
stocks of the clinical isolates CI #6, CI #10, CI #14, CI #15,
CI #16, CI #17, CI #18 and CI #19 were generated by coc-
ulture of peripheral blood mononuclear cells (PBMCs)
from a healthy donor with lymphocytes from an HIV-1-
infected person. Coreceptor usage of the viruses was
determined by viral replication in CXCR4- and CCR5-
transfected U87.CD4 cells.
Cells
The T-cell lines MOLT-4.CCR5 and Jurkat.CCR5 were
obtained from the MRC (London, UK). The CCR5-trans-
fected SupT1 T-cells were obtained earlier in our labora-
tory. The SupT1 cells used for this transfection were
obtained from the American Type Culture Collection
(Rockville, MD). The cells were cultured in RPMI 1640
medium (Gibco BRL, Gaithersburg, MD) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and
1% glutamine (Gibco BRL). Cell cultures were maintained
at 37°C in a humidified CO2-controlled atmosphere and
subcultivations were done every 2 to 3 days.
Human astroglioma U87 cells expressing human CD4
(U87.CD4) [52] were a kind gift of Dr. Dan Littman (Skir-
ball Institute of Biomolecular Medicine, New York Uni-
versity Medical Center, New York, NY) and were cultured
in Dulbecco's modified Eagle's medium (Gibco BRL) con-
taining 10% fetal bovine serum (FBS) (Hyclone, Perbio,
Erembodegem, Belgium), 0.01 M HEPES buffer (Gibco
BRL), and 0.2 mg/ml geneticin (G-418 sulfate) (Gibco
BRL). The cell cultures were maintained at 37°C in a
humidified CO2-controlled atmosphere and subcultiva-
tions were done every 2 to 3 days by digestion of the mon-
olayers with trypsin/EDTA (Gibco BRL).
The pTEJ-8 expression vectors encoding for the chemok-
ine receptors CCR5 and CXCR4 were cotransfected with
the pPUR selection vector encoding puromycin resistance
(CLONETECH Laboratories, Palo Alto, CA) into
U87.CD4 cells by the use of FuGENE 6 Tranfection Rea-
gent (Roche Molecular Biochemicals, Mannheim, Ger-
many) according to the Manufacturer's instructions.
Puromycin selection (1 µg/ml) is started after 24 hours.
We established a puromycin-resistant cell culture after 2
weeks. However, only 24% percent of the CCR5 and
CXCR4 positive cells were double-positive (as determined
by flow cytometry). To isolate these double-positive cells,
expressing both CCR5 and CXCR4, cells were stained with
a FITC-conjugated anti-CCR5 mAb (clone 2D7) and with
PE-conjugated anti-CXCR4 mAb (clone 12G5). Then,
double-positive cells were sorted using a FACSVantage flu-
orescence cell sorter (Becton Dickinson, San Jose, CA)
equipped with a Enterprise II laser (Coherent, Santa Clara,
CA) running at 250 mW.
Flow cytometric analyses
The antibodies used in this study were: FITC- and PE-con-
jugated mouse anti-human CCR5 (clone 2D7) (BD Bio-
sciences, San Jose, CA), PE-conjugated mouse anti-human
CXCR4 mAb (clone 12G5) (BD Biosciences) and PE-con-
jugated mouse anti-human CD4 (BD Biosciences). Cells
were digested with trypsin at least 1 hour before staining
to allow re-expression of the receptors on the cell surface.
Then cells were washed in PBS containing 2% FBS and for
each sample 0.5 × 106 cells were resuspended in 100 µl
PBS/FBS 2%. Thereafter, antibodies were added and sam-
ples were incubated for 30 minutes at room temperature.
After incubation, cells were washed two times with PBS,
fixed in 250 µl PBS containing 1% paraformaldehyde and
analysed on a FACScalibur flow cytometer (Becton Dick-
inson, San Jose, CA). As a control for aspecific background
staining, the cells were stained in parallel with Simultest
Control  γ1/γ2α FITC/PE (Becton Dickinson). Data were
analysed with CellQuest software (Becton Dickinson).
Calcium signalling assays
U87 cells were digested by trypsin and seeded out in gela-
tin-coated (0.2%) black-wall 96-well microplates (Costar,
Cambridge, MA) at a concentration of 2 × 104 cells per
well. To be able to monitor calcium signalling, cells were
loaded with the fluorescent calcium indicator Fluo-3/AM
(Molecular Probes, Leiden, The Netherlands) at 4 µM at
37°C for 45 minutes. After loading, cells were washed
with calcium flux assay buffer (Hanks' balanced salt solu-
tion (HBSS) (Gibco BRL, Gaitherburg, MD) containing 20
mM HEPES (Gibco) and 0.2% bovine serum albumin
(BSA) (Sigma Aldrich, St Louis, MO), pH 7.4) to remove
extracellular dye and thereafter 150 µl of the antagonists
(SCH-C and AMD3100) at different concentrations (1/5
dilutions), diluted in calcium flux assay buffer, were
added to the cells. After preincubation of the compounds
at 37°C for 10 minutes, the intracellular calcium signal-
ling in response to 100 ng/ml LD78β and to 20 ng/ml
SDF-1 was measured in all 96 wells simultaneously as a
function of time, using the Fluorometric Imaging PlateRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/2
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Reader (FLIPR) (Molecular Devices, Sunnyvale, CA) [53].
In the experiments where chemokines were added
sequentially, LD78β was added first at timepoint 20 sec-
onds and SDF-1 at timepoint 222 seconds after the start of
the experiment. Here, Fluo-3 loaded cells were preincu-
bated for 10 minutes with a mixture of SCH-C and
AMD3100 at a 1:1 ratio each at a final concentration of
1000 ng/ml. AMD3100 and SCH-C were synthesized as
described previously [19,20]. The CC-chemokine LD78β
was obtained from PeproTech (PeproTech, London, UK).
The CC-chemokine RANTES and the CXC-chemokine
SDF-1 were provided by Dr. I. Clark-Lewis (University of
British Columbia, Vancouver, BC, Canada).
HIV-1 infection assays
U87.CD4 cells transfected with CCR5, CXCR4 or both,
were digested by using trypsin. These cells and the MOLT-
4.CCR5, Jurkat.CCR5 and SupT1.CCR5 cells were washed
and resuspended at 5 × 104 cells/ml in medium and
seeded out in 24 well plates. HIV-1 laboratory strains BaL,
NL4.3 and HE were added at a final concentration of
respectively 250, 100 and 200 pg/ml p24 Ag for all cell
lines mentioned above. The viral input of the clinical iso-
lates was 5000 pg/ml p24 Ag for the
U87.CD4.CCR5.CXCR4 cells. To examine the antiviral
activity of the CCR5 or CXCR4 antagonists (SCH-C and
AMD3100) or the chemokines (RANTES, LD78β and
SDF-1) the cells were seeded out in 24-well plates already
containing compounds and chemokines at varying con-
centrations (1/5 dilutions). SCH-C and AMD3100 were
evaluated as single agents or as a mixture of both at a 1:1
ratio. Then, viruses were added after a preincubation
period of 10 minutes and the plates were maintained at
37°C in a humidified CO2-controlled atmosphere. After 2
days of infection, the original virus input was washed
away and fresh DMEM-based medium was added (con-
taining antagonists at the same concentrations as before).
The cytopathic effect (syncytium or giant cell formation)
in the virus-infected cell cultures was evaluated micro-
scopically at 5 days after infection. Then also, the superna-
tant was collected and analysed for virus content based on
the p24 core Ag ELISA (DuPont-Merck Pharmaceutical
Co., Wilmington, DE).
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